DDInter814 DDInter1625
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. The antibody is specifically directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). By binding to the CD33 antigen on tumors, the cytotoxic agent blocks the growth of cancerous cells and causes cell death. Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Gemtuzumab ozogamicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Moxifloxacin
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Gemtuzumab ozogamicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Gemtuzumab ozogamicin {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Gemtuzumab ozogamicin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Lomitapide
Gemtuzumab ozogamicin may lead to a major life threatening interaction when taken with Etanercept